Generics medicine industry unlikely to be impacted by Trump order: Indian Pharmaceutical Alliance

May 13, 2025

India's generics medicine industry is unlikely to be impacted by President Donald Trump's move to slash drug prices in the US drastically, said Sudarshan...

COVID-19: DCGI nod to Jubilant Generics to manufacture, sell remdesivir for 'restricted emergency use'

Jul 20, 2020

New Delhi [India], July 20 : The Drug Controller General of India (DCGI) has granted permission to pharma giant- Jubilant Generics Ltd to manufacture...

India healthcare sector growth to strengthen over next 3 years on new drug launches: Systematix Report

Feb 23, 2026

The domestic healthcare sector is expected to see stronger growth over the next three years supported by new drug launches, while earnings from the...

Trump's 100% tariff on patented drugs has limited impact on Indian pharma, rising protectionism a concern: CEO (Designate) Syngene International Limited

Apr 03, 2026

The recent decision by US President Donald Trump to impose a 100 per cent tariff on patented pharmaceutical imports to US is unlikely to...

Trump imposes 100% tariff on patented drug imports; revises metal duties

Apr 02, 2026

President Trump has signed executive orders imposing a 100% tariff on patented drug imports from countries like India to force "reshoring" to the US....

Healthcare sector to see modest revenue growth in Q4, margin pressure from us generics cliff: Systematix

Apr 15, 2026

India's healthcare sector is poised for high single-digit year-on-year revenue growth in Q4FY26, but EBITDA margins are set to "materially correct" as the loss...